Login / Signup

Recent drug development and treatments for fungal infections.

Madhura RoySonali KarhanaMd ShamsuzzamanMohd Ashif Khan
Published in: Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] (2023)
Fungal infections are now becoming a hazard to individuals which has paved the way for research to expand the therapeutic options available. Recent advances in drug design and compound screening have also increased the pace of the development of antifungal drugs. Although several novel potential molecules are reported, those discoveries have yet to be translated from bench to bedside. Polyenes, azoles, echinocandins, and flucytosine are among the few antifungal agents that are available for the treatment of fungal infections, but such conventional therapies show certain limitations like toxicity, drug interactions, and the development of resistance which limits the utility of existing antifungals, contributing to significant mortality and morbidity. This review article focuses on the existing therapies, the challenges associated with them, and the development of new therapies, including the ongoing and recent clinical trials, for the treatment of fungal infections. Advancements in antifungal treatment: a graphical overview of drug development, adverse effects, and future prospects.
Keyphrases
  • clinical trial
  • candida albicans
  • randomized controlled trial
  • oxidative stress
  • type diabetes
  • coronary artery disease
  • cardiovascular disease
  • cell wall
  • risk assessment
  • phase iii
  • adverse drug